Australia markets closed

Equillium, Inc. (EQ)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.8800+0.1600 (+3.39%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close4.7200
Open4.8100
Bid4.5500 x 1100
Ask4.9500 x 1800
Day's range4.6500 - 4.9800
52-week range4.0800 - 11.3300
Volume46,958
Avg. volume71,204
Market cap143.73M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date10 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.00
  • Business Wire

    Equillium to Present at Two Upcoming Investor Conferences

    LA JOLLA, Calif., November 09, 2021--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in fireside chat presentations at the Stifel 2021 Virtual Healthcare Conference and the Jefferies Virtual London Healthcare Conference.

  • Business Wire

    Equillium Presents Interim Safety Data from First Cohort of Asthma Patients in Phase 1b EQUIP Study at the American College of Allergy, Asthma & Immunology Meeting

    LA JOLLA, Calif., November 05, 2021--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today reported interim data from the first cohort in its randomized, placebo-controlled Phase 1b EQUIP study for itolizumab in patients with moderate to severe uncontrolled asthma. These data, which summarize early safety and clinical activity, are part of a poster presentation available

  • Business Wire

    Equillium Presents Clinical Data from EQUALISE Phase 1b Study in Lupus Patients at the American Society of Nephrology Annual Meeting

    LA JOLLA, Calif., November 05, 2021--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced interim data from the Type A portion of the Phase 1b EQUALISE study that showed promising clinical activity in patients with systemic lupus erythematosus (SLE), and pharmacokinetic and pharmacodynamic data supporting the anti-CD6 mechanism of itolizumab. The data were pre